A slew of developments in women's healthcare emerged in 2023: In May, the Food and Drug Administration (FDA) approved the first-of-its-kind drug to treat menopausal hot flashes. In June, it approved the first over-the-counter birth control pill.
The latest development is zuranolone, brand name Zurzuvae. On August 4, 2023, the FDA approved Zurzuvae, the first pill specifically for postpartum depression. Before then, healthcare professionals had to administer intravenous injections for this potentially life-threatening condition.
